MicroVue™ C3a Plus EIA
The MicroVue C3a Plus Enzyme Immunoassay is for the measurement of C3a in plasma and serum.
Product Specifications
Citations | 66 |
---|---|
Specimen |
Serum/EDTA Plasma 10 μL |
LLOQ | 0.023 ng/mL |
ULOQ | 2.531 ng/mL |
Assay Time | 2.5 hours |
Cross Reactivity |
African Green Monkey, Cynomolgous monkey, Rhesus monkey |
Ordering Information
Catalog Number | A031 |
---|---|
Catalog Number (CE) | A032 |
Size | 96 wells/test |
Price (USD) | $725.00 |
Price (EURO) | 640,00 € |
Contact us
US Phone | +1 (858) 552 1100 |
---|---|
EU Phone | +353 (91) 412 474 |
US Email | contact-us@quidelortho.com |
EU Email | contact-emea@quidelortho.com |
- Specifications
- Citations
- Certificate of Analysis
Specifications
Description |
The MicroVue C3a Plus Enzyme Immunoassay is for the measurement of C3a in plasma and serum. |
---|---|
Size | 96 wells/test |
Form |
96 well plate with 12 eight-well strips in a resealable foil pouch |
Specimen | Serum/EDTA Plasma 10 μL |
Limit of Detection (LOD) | 0.012 ng/mL |
Lower Limit of Quantitation (LLOQ) | 0.023 ng/mL |
Upper Limit of Quantitation (ULOQ) | 2.531 ng/mL |
Intra Assay | 4.5–5.3% |
Inter Assay | 5.9–19.6% |
Standards | 5 |
Controls | 2 |
Sample Values |
Serum 71.0–589.2 ng/mL, EDTA Plasma 33.8–268.1 ng/mL |
Assay Time | 2.5 hours |
Cross Reactivity |
African Green Monkey, Cynomolgous monkey, Rhesus monkey |
Storage |
Store the unopened kit at 2°C to 8°C. Refer to Product Insert for additional storage details. |
Background |
Under normal conditions, activation of the classical, alternative, or lectin complement pathways results in the formation of a C3 convertase multi-molecular enzyme capable of cleaving C3 to C3a and C3b. C3a is a low molecular weight (approximately 9kD) protein fragment of 77 amino acids. C3a is rapidly metabolized by the serum enzyme carboxypeptidase N to a more stable, 76 amino acid form, C3a des-Arg. For convenience, both forms will be referred to as “C3a” for purposes of this documentation. The MicroVue C3a Plus assay, a rapid, highly specific and quantitative procedure for measuring C3a levels, is designed for investigations into the role or status of complement pathway activation in numerous research settings, and for monitoring the generation of C3a in vivo or in vitro. C3a has been shown to increase vascular permeability, to be spasmogenic and chemotactic, and to induce the release of pharmacologically active mediators from a number of cell types. The role of C3a in the pathogenesis of inflammatory reactions seen in gram-negative bacterial sepsis, trauma, ischemic heart disease, cerebral ischemia, post dialysis syndrome and several autoimmune diseases (including rheumatoid arthritis, lupus erythematosus, and acute glomerulonephritis) is well documented. |
Citations
Title | Year | Applications | Sample Species | Sample | Sample Details |
---|---|---|---|---|---|
2014 | ELISA |
Cell Culture |
SKOV3ip1 cells |
||
Decreased immune response in monkeys administered a human T-effector cell agonist (OX40) antibody. |
2020 | ELISA |
Cynomolgus Monkey |
Plasma, Serum |
T-effector cell agonist (OX40) antibody |
2014 | ELISA |
Human |
Plasma |
Neuromyelitis optica |
|
2016 | ELISA |
Human |
ARPE-19 Cells |
||
2017 | ELISA |
Human |
Plasma |
Hereditary Angioedema |
|
2019 | ELISA |
Human |
Plasma |
ANCA-AAV |
|
2019 | ELISA |
Human |
Aqueous humour |
Age-Related Macular Degeneration |
|
Subvisible Particles in IVIg Formulations Activate Complement in Human Serum. |
2020 | ELISA |
Human |
Serum |
IVIg formulations |
2019 | ELISA |
Human |
Plasma |
aHUS |
|
Complement factor H contributes to mortality in humans and mice with bacterial meningitis. |
2019 | ELISA |
Human |
CSF |
Bacterial meningitis |
Complement Activation Profile of Patients With Primary Focal Segmental Glomerulosclerosis. |
2020 | ELISA |
Human |
Plasma |
FSGS |
Complement Activation Profile of Patients With Primary Focal Segmental Glomerulosclerosis. |
2020 | ELISA |
Human |
Serum |
FSGS |
2020 | ELISA |
Human |
Plasma |
||
2020 | ELISA |
Human |
Serum |
||
2020 | ELISA |
Human |
Serum |
SiNP coated proteins |
|
2020 | ELISA |
Human |
Plasma |
COVID-19 |
|
Complement Activation in the Vitreous of Patients With Proliferative Diabetic Retinopathy. |
2020 | ELISA |
Human |
Plasma, Vitreous Humor |
Proliferative Diabetic Retinopathy |
2020 | ELISA |
Human |
Plasma |
COVID-19 |
|
2020 | ELISA |
Human |
Serum |
Lupus Nephritis, Thrombotic Microangiopathy |
|
2020 | ELISA |
Human |
Urine |
Lupus Nephritis, Thrombotic Microangiopathy |
|
2021 | ELISA |
Human |
Serum |
COVID-19 |
|
von Willebrand factor variants in C3 glomerulopathy: A Chinese cohort study. |
2021 | ELISA |
Human |
Plasma |
C3G |
von Willebrand factor variants in C3 glomerulopathy: A Chinese cohort study. |
2021 | ELISA |
Human |
Urine |
C3G |
2021 | ELISA |
Human |
Plasma |
||
2021 | ELISA |
Human |
Peritoneal fluid (w/ Endometriosis) |
||
Thromboinflammation Supports Complement Activation in Cancer Patients With COVID-19. |
2021 | ELISA |
Human |
Plasma |
Cancer, COVID-19 |
Thromboinflammation Supports Complement Activation in Cancer Patients With COVID-19. |
2021 | ELISA |
Human |
Plasma |
COVID-19 |
2021 | ELISA |
Human |
Plasma |
||
2022 | ELISA |
Human |
Plasma |
Heat-related illnesses |
|
Comparison of Complement Pathway Activation in Autoimmune Glomerulonephritis. |
2022 | ELISA |
Human |
Urine |
AAV, FSGS, IgAN, MN, and LN |
2022 | ELISA |
Human |
Plasma |
COVID-19 |
|
2022 | ELISA |
Human |
Plasma |
Age-Related Macular Degeneration |
|
The Role of Complement in Microangiopathic Lesions of IgA Nephropathy. |
2022 | ELISA |
Human |
Serum |
IgA Nephropathy |
2022 | ELISA |
Human |
Plasma |
Hemodialysis |
|
2022 | ELISA |
Human |
Plasma |
Obesity |
|
C3a and C5b-9 Differentially Predict COVID-19 Progression and Outcome. |
2022 | ELISA |
Human |
Plasma |
COVID-19 |
Absence of Gal epitope prolongs survival of swine lungs in an ex vivo model of hyperacute rejection |
2011 | ELISA |
Human |
Plasma |
|
Complement C3 serum levels in anorexia nervosa: a potential biomarker for the severity of disease |
2011 | ELISA |
Human |
Serum |
|
2011 | ELISA |
Human |
Peripheral blood mononuclear cells |
||
A prevalent C3 mutation in aHUS patients causes a direct C3 convertase gain of function |
2012 | ELISA |
Human |
Serum |
GEnCs and HUVEC exposed |
2012 | ELISA |
Human |
Plasma |
||
2013 | ELISA |
Human |
Serum |
Borrelia valaisiana incubated |
|
Complement activation in pediatric patients with recurrent acute otitis media |
2013 | ELISA |
Human |
Ear Fluid (MEE) |
|
Complement activation in pediatric patients with recurrent acute otitis media |
2013 | ELISA |
Human |
Serum |
|
Zonulin as prehaptoglobin2 regulates lung permeability and activates the complement system |
2013 | ELISA |
Human |
Serum |
|
2013 | ELISA |
Human |
CSF |
||
Human factor H-related protein 2 (CFHR2) regulates complement activation |
2013 | ELISA |
Human |
Serum |
|
2014 | ELISA |
Human |
Plasma |
Lupus Nephritis |
|
2014 | ELISA |
Human |
Plasma |
||
Cerebrospinal fluid inflammatory markers in patients with Listeria monocytogenes meningitis |
2014 | ELISA |
Human |
CSF |
Listeria meningitis |
2015 | ELISA |
Human |
Plasma |
||
2015 | ELISA |
Human |
ARPE-19 Cells |
||
2015 | ELISA |
Human |
Serum |
||
2015 | ELISA |
Human |
Serum |
Porcine articular chondrocytes |
|
Platelet-borne complement proteins and their role in platelet–bacteria interactions |
2016 | ELISA |
Human |
Plasma |
|
2017 | ELISA |
Human |
Plasma |
||
2017 | ELISA |
Human |
Plasma |
ANCA-AAV |
|
2017 | ELISA |
Human |
Plasma |
||
2020 | ELISA |
Human |
Plasma |
Immune‐mediated thrombotic thrombocytopenic purpura |
|
Complement activation during painful crisis in sickle cell anemia |
1995 | ELISA |
Human |
Plasma |
Sickel Cell Anemia |
2023 | ELISA |
Human |
Supernatent |
Latex beads with poE2, apoE3, or apoE4 |
|
2023 | ELISA |
Human |
Plasma |
Diabetes |
|
2024 | ELISA |
Human |
Plasma |
Diabetes, Type 1 |
|
Novel adenovirus vectors 'capsid-displaying' a human complement inhibitor |
2010 | ELISA |
Human, Primate |
Serum |
|
Complement Protein C3 Suppresses Axon Growth and Promotes Neuron Loss |
2017 | ELISA |
Mouse |
Neuron Cells |
|
2002 | ELISA |
Rhesus Monkey |
Serum |